This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

NAME OF THE MEDICINAL PRODUCT

QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gram of gel contains 150 mcg of ingenol mebutate. Each tube contains 70 mcg of ingenol mebutate in 0.47 g of gel. For the full list of excipients, see section 6.1.

PHARMACEUTICAL FORM

CLINICAL PARTICULARS

Posology and method of administration

One tube of Picato 150 mcg/g gel (containing 70 mcg ingenol mebutate) should be applied once daily to the affected area for 3 consecutive days.

No dose adjustment is required (see section 5.1). Methodofadministration The content of one tube covers a treatment area of 25 cm2 (e.g. 5 cm x 5 cm). The content of the tube should be applied to one treatment area of 25 cm2. The tube is for single use only and should be discarded after use (see section 6.6). The gel from the tube should be squeezed onto a fingertip and spread evenly over the entire treatment area, allowing it to dry for 15 minutes. The content of one tube should be used for one treatment area of 25 cm2. For single use only. For treatment of the neck: If more than half of the treatment area is located in the upper part of the neck, the posology for face and scalp should be used. If more than half of the treatment area is located in the lower part of the neck, the posology for trunk and extremities should be used. Patients should be instructed to wash their hands with soap and water, immediately after applying Picato. If treating the hands, only the fingertip which is used for applying the gel should be washed. Washing and touching the treated area should be avoided for a period of 6 hours after application of Picato. After this period, the treatment area may be washed using mild soap and water. Picato should not be applied immediately after taking a shower or less than 2 hours before bedtime. The treated area should not be covered with occlusive bandages after Picato is applied. Optimal therapeutic effect can be assessed approximately 8 weeks after treatment. If the treated area shows an incomplete response at the follow-up examination, the treatment should be carefully re- evaluated and management reconsidered. Clinical data on treatment for more than one treatment course of 2 or 3 consecutive days is not available. Clinical data on treatment of more than one area is not available. Clinical data on treatment in immunocompromised patients is not available, but systemic risks are not expected since ingenol mebutate is not absorbed systemically.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Contact with the eyes should be avoided. If accidental exposure occurs, the eyes should be flushed immediately with large amounts of water, and the patient should seek medical care as soon as possible. Eye disorders such as eye pain, eyelid oedema and periorbital oedema should be expected to occur after accidental eye exposure of Picato (see section 4.8).

Picato must not be ingested. If accidental ingestion occurs the patient should drink plenty of water and seek medical care.

Administration of Picato is not recommended until the skin is healed from treatment with any previous medicinal product or surgical treatment and should not be applied to open wounds or damaged skin where the skin barrier is compromised. Picato should not be used near the eyes, on the inside of the nostrils, on the inside of the ears or on the lips.

Local skin responses such as erythema, flaking/scaling, and crusting should be expected to occur after cutaneous application of Picato (see section 4.8). Localised skin responses are transient and typically occur within 1 day of treatment initiation and peak in intensity up to 1 week following completion of treatment. Localised skin responses typically resolve within 2 weeks of treatment initiation when treating areas on the face and scalp and within 4 weeks of treatment initiation when treating areas on the trunk and extremities. Treatment effect may not be adequately assessed until resolution of local skin responses.

Studies have been conducted to assess the effects of UV irradiation of the skin following single and multiple applications of ingenol mebutate gel, 100 mcg/g. Ingenol mebutate gel did not demonstrate any potential for photo irritation or photo allergic effects. However, due to the nature of the disease, excessive exposure to sunlight (including sunlamps and tanning beds) should be avoided or minimised.

Lesions clinically atypical for actinic keratosis or suspicious for malignancy should be biopsied to determine appropriate treatment.

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Interactions with systemically absorbed medicinal products are considered unlikely as Picato is not absorbed systemically.

Fertility, pregnancy and lactation

There are no data from the use of ingenol mebutate in pregnant women. Animal studies showed slight embryo-fetal toxicity (see section 5.3). Risks to humans receiving cutaneous treatment with ingenol mebutate are considered unlikely as Picato is not absorbed systemically. As a precautionary measure, it is preferable to avoid the use of Picato during pregnancy.

No effects on the breastfed newborn/infant are anticipated as Picato is not absorbed systemically. The nursing mother should be instructed that physical contact between her newborn/infant and the treated area should be avoided for a period of 6 hours after application of Picato.

Effects on ability to drive and use machines

Undesirable effects

Summaryofthesafetyprofile

The most frequently reported adverse reactions are local skin responses including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration at the application site of ingenol mebutate gel, see table 1 for MedDRA terms. Following the application of ingenol mebutate, most patients (>95%) experienced one or more local skin response(s). Infection at the application site has been reported when treating face and scalp.

Tabulatedlistofadversereactions

Table 1 reflects exposure to Picato 150 mcg/g or 500 mcg/g in 499 patients with actinic keratosis treated in four vehicle controlled phase 3 studies enrolling a total of 1,002 patients. Patients received field treatment (area of 25 cm2) with Picato at concentrations of 150 mcg/g or 500 mcg/g or vehicle once daily for 3 or 2 consecutive days respectively. The table below presents adverse reactions by MedDRA system organ class and anatomical location. Frequencies have been defined according to the following convention: Very common (>=1/10); common (>=1/100 to <1/10); uncommon (>=1/1,000 to <1/100); rare (>=1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1 Adverse reactions by MedDRA System Organ Classification
	Frequency
System Organ Class	Face and scalp	Trunk and extremities
Infections and infestations
Application site pustules	Very common	Very common
Application site infection	Common
Nervous system disorders
Headache	Common
Eye disorders *
Eye lid oedema	Common
Eye pain	Uncommon
Periorbital oedema	Common
General disorders and administration site conditions
Application site erosion	Very common	Very common
Application site vesicles	Very common	Very common
Application site swelling	Very common	Very common
Application site exfoliation	Very common	Very common
Application site scab	Very common	Very common
Application site erythema	Very common	Very common
Application site pain * *	Very common	Common
Application site pruritus	Common	Common
Application site irritation	Common	Common
Application site discharge	Uncommon
Application site paraesthesia	Uncommon	Uncommon
Application site ulcer	Uncommon	Uncommon
Application site warmth		Uncommon

*: Application site swelling on the face or scalp may gravitate to the eye area * *: Including application site burning

Descriptionofselectedadversereactions

The incidence of local skin responses that occurred at an incidence >1% in both the 'face/scalp' and the 'trunk/extremities', respectively are: application site erythema (94% and 92%), application site exfoliation (85% and 90%), application site scab (80% and 74%), application site swelling (79% and 64%), application site vesicles (13% and 20%), application site pustules (43% and 23%) and application site erosion (31% and 25%). Severe local skin responses occurred with an incidence of 29% on the face and scalp and with an incidence of 17% on the trunk and extremities. The incidence of severe local skin responses that occurred at an incidence >1% in both the 'face/scalp' and the 'trunk/extremities', respectively are: application site erythema (24% and 15%), application site exfoliation (9% and 8%), application site scab (6% and 4%), application site swelling (5% and 3%) and application site pustules (5% and 1%).

Long-termfollowup

A total of 198 patients with complete clearance at day 57 (184 treated with Picato and 14 treated with vehicle) were followed for additionally 12 months. The results did not change the safety profile of Picato (see section 5.1). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via .

thenationalreportingsystem

listedinAppendixV

Overdose

Overdosing of Picato could result in an increased incidence of local skin responses. Management of overdose should consist of treatment of clinical symptoms.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Pharmacotherapeutic group: Antibiotics and chemotherapeutics for dermatological use, other chemotherapeutics, ATC code: D06BX02.

The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised. In vivo and in vitro models have shown a dual mechanism of action for the effects of ingenol mebutate: 1) induction of local lesion cell death and 2) promoting an inflammatory response characterised by local production of proinflammatory cytokines and chemokines and infiltration of immunocompetent cells.

Results from two clinical trials on biological effects of ingenol mebutate have shown that topical administration induced epidermal necrosis and a profound inflammatory response in both epidermis and the upper dermis of the treated skin, dominated by infiltrating T cells, neutrophils and macrophages. Necrosis in the dermis was rarely observed. Gene expression profiles of skin biopsies from the treated areas is suggestive of inflammatory responses and response to wounding, which is consistent with the histology assessments. Non-invasive examination of the treated skin by reflectance confocal microscopy have shown that the skin changes induced by ingenol mebutate were reversible, with almost complete normalisation of all measured parameters on day 57 after treatment, which is supported also by clinical findings and studies in animals.

The efficacy and safety of Picato 150 mcg/g, administered on the face or scalp for 3 consecutive days was studied in two double-blind, vehicle-controlled, clinical studies including 547 adult patients. Likewise the efficacy and safety of Picato 500 mcg/g, administered on the trunk and extremities for 2 consecutive days was studied in two double-blind, vehicle-controlled, clinical studies including 458 adult patients. Patients continued in the studies for an 8 week follow-up period during which they returned for clinical observations and safety monitoring. Efficacy, measured as complete and partial clearance rate, as well as median percent reduction, was assessed at day 57 (see table 2). Patients had 4 to 8 clinically typical, visible, discrete, non-hyperkeratotic, non-hypertrophic, actinic keratosis lesions within a contiguous 25 cm2 treatment area on the face or scalp or on the trunk or extremities. On each scheduled dosing day, the study gel was applied to the entire treatment area. The compliance rate was high, with 98% of the patients completing these studies. Study patients ranged from 34 to 89 years of age (mean 64 and 66 years, respectively, for the two strengths) and 94% had Fitzpatrick skin type I, II, or III. At day 57, patients treated with Picato had higher complete and partial clearance rates than patients treated with vehicle gel (p<0.001). The median percent reduction in actinic keratosis lesions was higher in the group treated with ingenol mebutate compared to the vehicle group (see table 2).

The level of efficacy varied between the individual anatomical locations. Within each location the complete and partial clearance rates were higher in the group treated with ingenol mebutate compared to the vehicle group (see table 3 and 4).

Safety of Picato 150 mcg/g treatment for 3 days or Picato 500 mcg/g treatment for 2 days was assessed up to day 57, the majority of the reported adverse reactions and local skin responses were mild to moderate in intensity and all resolved without sequelae. Statistically significant differences in patient reported outcomes were observed in favour of patients receiving Picato compared to those receiving vehicle gel. Higher mean patient global satisfaction scores, indicating a higher level of overall satisfaction, were seen in the ingenol mebutate groups compared to the vehicle groups (p<0.001) as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).

Three prospective, observational long term 1 year follow-up studies were conducted to evaluate sustained efficacy by recurrence of actinic keratosis lesions in the treatment field, and safety in patients who had received treatment with Picato. One study included patients treated with Picato 150 mcg/g on the face or scalp for 3 days and two studies included patients treated with Picato 500 mcg/g on the trunk or extremities for 2 days. Only those patients who achieved complete clearance in the treated area at the end of the phase 3 studies (day 57) were eligible for long term follow-up. Patients were followed every 3 months for 12 months (see table 5).

At end of study (day 57), the rate of squamous cell carcinoma (SCC) reported in the treatment area was comparable in patients treated with ingenol mebutate gel (0.3%, 3 of 1,165 patients) and in vehicle treated patients (0.3%, 2 of 632 patients) in the actinic keratosis clinical studies conducted with ingenol mebutate gel. SCC in the treatment area was reported in no patients (0 of 184 patients previously treated with ingenol mebutate gel) in the three prospective, observational long term 1 year follow-up studies.

In a double-blind, vehicle-controlled study to evaluate systemic exposure, Picato 500 mcg/g, from 4 tubes, was applied to a 100 cm2 contiguous treatment area daily for 2 consecutive days. Results demonstrated no systemic absorption. Picato 500 mcg/g was well tolerated when applied to a contiguous treatment area of 100 cm2 on the trunk and extremities.

The European Medicines Agency has waived the obligation to submit the results of studies with Picato in all subsets of the paediatric population in actinic keratosis (see section 4.2 for information on paediatric use).

Of the 1,165 patients treated with Picato in the actinic keratosis clinical studies conducted with ingenol mebutate gel, 656 patients (56%) were 65 years and older, while 241 patients (21%) were 75 years and older. No overall differences in safety or efficacy were observed between younger and older patients.

Pharmacokinetic properties

The systemic pharmacokinetic profile of ingenol mebutate and its metabolites has not been characterised in humans due to the absence of quantifiable whole blood levels following cutaneous administration. No systemic absorption was detected at or above the lower limit of detection (0.1 ng/mL) when Picato 500 mcg/g from 4 tubes was applied to an area of 100 cm2 on the dorsal forearm in actinic keratosis patients once daily for 2 consecutive days. In vitro study results demonstrate that ingenol mebutate does not inhibit or induce human cytochrome P450 isoforms.

Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity and genotoxicity. The non-clinical safety studies demonstrate that cutaneous administration of ingenol mebutate gel is well tolerated with any skin irritation being reversible and a negligible risk of systemic toxicity under the recommended conditions of use. In rats, ingenol mebutate was not associated with fetal developmental effects at IV doses up to 5 mcg/kg/day (30 mcg/m2/day). In rabbits there were no major abnormalities. Minor fetal abnormalities or variants were observed in the fetuses of treated dams at doses of 1 mcg/kg/day (12 mcg/m2/day).

PHARMACEUTICAL PARTICULARS

List of excipients

Isopropyl alcohol Hydroxyethylcellulose Citric acid monohydrate Sodium citrate Benzyl alcohol Purified water

Incompatibilities

Shelf life

Special precautions for storage

Store in a refrigerator (2oC-8oC). Tubes should be discarded after first opening.

Nature and contents of container

Single-dose laminate tubes with inner layer of High Density Polyethylene (HDPE) and aluminium as the barrier layer. Caps of HDPE. Picato 150 mcg/g gel is available in a carton containing 3 tubes with 0.47 g of gel each.

Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

MARKETING AUTHORISATION HOLDER

MARKETING AUTHORISATION NUMBER(S)

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Table 2 Rates of subjects with complete and partial clearance and median percent (%) lesion reduction in actinic keratosis
	Face and scalp		Trunk and extremities
	Picato 150 mcg/g (n=277 )	Vehicle (n=270 )	Picato 500 mcg/g (n=226 )	Vehicle (n=232 )
Complete Clearance Rate a	42.2% d	3.7%	34.1% d	4.7%
Partial Clearance Rate b (>= 75%)	63.9% d	7.4%	49.1% d	6.9%
Median % Reduction c	83%	0%	75%	0%
a Complete clearance rate was defined as the proportion of patients with no (zero) clinically visible actinic keratosis lesions in the treatment area. b Partial clearance rate was defined as the percentage of patients in whom 75% or more of the number of baseline actinic keratosis lesions were cleared. c Median percent (%) reduction in actinic keratosis lesions compared to baseline. d p<0.001; compared to vehicle by logistic regression with treatment, study and anatomical location.

Table 3 Number and percent (95% CI) of subjects achieving complete and partial clearance at day 57 by anatomical location face and scalp
	Complete Clearance		Partial Clearance( >= 75%)
	Picato 150 mcg/g (n=277 )	Vehicle (n=270 )	Picato 150 mcg/g (n=277)	Vehicle (n=270)
Face	104/220 47% (41-54%)	9/220 4% (2-8%)	157/220 71% (65-77%)	18/220 8% (5-13%)
Scalp	13/57 23% (13-36%)	1/50 2% (0-11%)	20/57 35% (23-49%)	2/50 4% (1-14%)
Table 4 Number and percent (95% CI) of subjects achieving complete and partial clearance at day 57 by anatomical location trunk and extremities
	Complete clearance		Partial clearance ( >= 75%)
	Picato 500 mcg/g (n=226)	Vehicle (n=232)	Picato 500 mcg/g (n=226)	Vehicle (n=232)
Arm	49/142 35% (27-43%)	7/149 5% (2-9%)	75/142 53% (44-61%)	11/149 7% (4-13%)
Back of Hand	10/54 19% (9-31%)	0/56 0% (0-6%)	16/54 30% (18-44%)	1/56 2% (0-10%)
Chest	11/14 79% (49-95%)	2/11 18% (2-52%)	12/14 86% (57-98%)	2/11 18% (2-52%)
Other a	7/16 44% (20-70%)	2/16 13% (2-38%)	8/16 50% (25-75%)	2/16 13% (2-38%)
a Other includes shoulder, back, leg.

Table 5 Rate of recurrence of actinic keratosis lesions
	Picato 150 mcg/g gel Face and scalp (n=108 )	Picato 500 mcg/g gel Trunk and extremities (n=76 c )
Recurrence Rate 12 months KM estimate (95% CI) a	53.9% (44.6-63.7)	56.0% (45.1-67.6)
Lesion Based Recurrence Rate b 12 months Mean (SD)	12.8% (19.1)	13.2% (23.0)
a The recurrence rate is the Kaplan-Meier (KM) estimate at the target study date of the visit expressed as a percentage (95% CI). Recurrence was defined as any identified actinic keratosis lesion in the previously treated area for patients who achieved complete clearance at day 57 in the previous phase 3 studies. b The lesion-based recurrence rate for each patient defined as the ratio of the number of actinic keratosis lesions at 12 months to the number of lesions at baseline in the previous phase 3 studies. c Of these, 38 subjects were previously treated in a vehicle controlled phase 3 study and 38 subjects were previously treated in an uncontrolled phase 3 study.

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS